Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer-Reference-Cited by-同舟云学术

Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer

Published:2019-07-24 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Deen Surrin S.,Priest Andrew N.^ORCID,McLean Mary A.,Gill Andrew B.,Brodie Cara,Crawford Robin,Latimer John,Baldwin Peter,Earl Helena M.,Parkinson Christine,Smith Sarah,Hodgkin Charlotte,Patterson Ilse,Addley Helen,Freeman Susan,Moyle Penny,Jimenez-Linan Mercedes,Graves Martin J.^ORCID,Sala Evis,Brenton James D.^ORCID,Gallagher Ferdia A.^ORCID

Funder

Cancer Research UK

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-47195-4.pdf

Reference40 articles.

1. Colombo, N. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology 21, v23–v30 (2010).

2. Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 363, 943–953 (2010).

3. McGuire, W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine 334, 1–6 (1996).